Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions

Post COVID-19 Syndrome

Interventions

BIOLOGICAL

HB-adMSCs (allogeneic)

HB-adMSCs allogenic

OTHER

Placebo

Placebo comarator

Trial Locations (1)

Hope Biosciences Research Foundation, Sugar Land

All Listed Sponsors

lead

Hope Biosciences Research Foundation

INDUSTRY